|
Orexigen on PE Week Wire
PE Week Wire
Thursday, April 26, 2007 Orexigen Therapeutics Inc., a San Diego-based neuroscience company focused on the treatment of obesity, priced seven million common shares at $12 per share, for an IPO take of approximately $84 million. It had originally filed to sell six million shares at between $11 and $13 per share. Orezigen will trade on the Nasdaq under ticker symbol OREX, while Merrill Lynch and JPMorgan served as co-lead underwriters. The company has raised around $76 million in total VC funding from firms like Domain Associates (21.3% pre-IPO stake), Kleiner Perkins (20%), Sofinnova Ventures (15%), Scale Venture Partners (14.8%), Montreaux Equity Partners (7.4%), Morgenthaler Partners (5.9%), MPM BioEquities and Wasatch Advisors. www.orexigen.com
|
